Compare Incyte Corporation (INCY) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs M&T Bank Corporation — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while M&T Bank Corporation trades at $248.99 (market cap $36.15B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays a 2.41% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MTB | |
|---|---|---|
Market Cap | $23.11B | $36.15B |
Sector | Health | Financials |
52-Week High | $118.52 | $254.04 |
52-Week Low | $67.38 | $178.63 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
M&T Bank (MTB) trades at $249.54, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 13.19 and net income margin of 30.85%, supported by robust loan growth and net interest income as highlighted in Q2 2026 results. Analyst consensus is a buy with a $253.68 price target, though the majority of ratings are hold.
The outlook for MTB is positive due to solid earnings performance and healthy credit quality, but risks include elevated costs and macroeconomic pressures. Investment opportunity lies in its valuation and dividend yield, while investors should monitor expense management and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
